This paper will give a preview of the soon to come non-compartmental pharmacokinetic analysis CDISC ADaM standard (ADNCA). ADNCA will be the submission data set that is sent to the PK scientist for calculation of non-compartmental PK parameters. We will present the proposed guidance and give an overview of the steps involved in developing this standard for analysis and submission to the FDA.
The ADNCA dataset will adhere closely to the BDS structure. The dataset itself will contain a combination of PK concentration data, its corresponding dosing data, and any additional data necessary to complete the non-compartmental analysis. The inclusion of this extra data is necessary, in part, because of the need to present timing variables related to the concentration event and dosing time. We will discuss the rationale for those timing variables as well as several other variables that are commonly of interest to the PK scientist.
In addition, the ADNCA data standard will support non-compartmental analyses, PK and PD data review, and could be utilized for tabular and graphical presentation of the data. However, ADNCA will not be suitable for population PK modeling analysis and is not intended to be used for presentation of the results of the PK analysis.
The ADNCA standard has been in development for some time and has gone through multiple rounds of revision. The ADaM sub-team has delivered a draft to the ADaM leadership team and the two continue to work together.
Pharmacokinetics, or PK, is the monitoring of the concentration level over time of an analyte within a human (or animal) body. The analyte is typically an active ingredient of a drug, or an element such as sodium or potassium, or a chemical compound which occurs naturally in blood or other body fluids, such as creatinine or bilirubin. PK data collection for an active drug compound is performed routinely in all clinical trials since it is a critical part of measuring the safety and efficacy of an experimental treatment and in determining the treatment dose amount, frequency, and time-release profile.
No matter what anybody thinks about remote workers, employers should understand the growing impact of flexible work arrangements. About 43 percent of survey takers said that they worked remotely at least sometimes, according to a recent Gallup poll.
In Part 1, we will discuss a general overview of how Pharmacokinetics and Pharmacodynamics (PK/PD) plays a key role with 3 key stakeholders: Patients, Drug Companies, and the Federal Drug Administration.
Florence Nightingale began to record data on patients, most notably, credited as being one of the first to use picture graphs and statistical analysis reports (something DataCeutics knows a bit about!).
Our last dog, Baxter, was a rescue dog and we had fallen in love with him over six years ago. His death came as a shock. So after about a week of somber mourning, the kids and I decided that we might want to look for another rescue.
“I could hardly believe the generosity of these kids and their parents,” Dave Ferdock says. “It was overwhelming that such kindness by so many, was shown to people our students didn’t even know.” He continued, "Altogether, fifty backpacks were collected and filled with a myriad of school necessities."
Finding good employees is a challenge every industry faces. Finding the best employees who fit with your culture and have the right skills and expertise to meet client expectations is a bigger challenge.
“For the past six years, I have been volunteering in Allentown, Pennsylvania in drug and alcohol abuse treatment facilities, says Matthew Ferdock, CEO of DataCeutics. “During the Holidays this past year, I reflected back on how many people feel the weight of loneliness and take to the bottle or reach for drugs to avoid their feelings. For them, living life is nearly impossible. Our goal as volunteers is to help them make it hour-to-hour,” he says.
Around the time CDISC was gaining momentum, my partner, and President of DataCeutics, Paul Gilbert established an internal group, the CDISC Center of Excellence (CoE) whose mission was to inform the rest of the company on new developments and challenges to implementing standards across the pharmaceutical/biotech research landscape.